cost-effectiveness evaluation of quadrivalent human papilloma virus vaccine for hpv-related disease in iran

human papilloma virus (hpv) vaccine recently has been added to the iran drug list, decision makers need information beyond that available from rcts to recommend funding for this vaccination program to add it to the national immunization program in iran. modeling and economic studies have addressed some of those information needs in foreign countries. in order to determine the long term benefit of this vaccine and impact of vaccine program on the future rate of cervical cancer in iran, we described a model, based on the available economic and health effects of human papilloma virus (hpv), to estimate the cost-effectiveness of hpv vaccination of 15-year-old girls in iran. our objective is to estimate the cost-effectiveness of hpv vaccination in iran against cervical cancer based on available data; incremental cost-effectiveness ratio (icer) calculations were based on a model comparing a cohort of 15-year-old girls with and without vaccination. we developed a static model based on available data in iran on the epidemiology of hpv related health outcome. the model compared the cohort of all 15-year old girls alive in the year 2013 with and without vaccination. the cost per qaly, which was found based on our assumption for the vaccination of 15-years old girl to current situation was 439,000,000 iranian rial rate (irr). by considering the key parameters in our sensitivity analysis, value varied from 251,000,000 irr to 842,000,000 irr. in conclusion, quadrivalent hpv vaccine (gardasil) is not cost-effective in iran based on the base-case parameters value.